Torrent Pharmaceuticals Limited

NSEI:TORNTPHARM 주식 보고서

시가총액: ₹940.7b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Torrent Pharmaceuticals 미래 성장

Future 기준 확인 5/6

Torrent Pharmaceuticals (는) 각각 연간 20.4% 및 11.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 28.4% 로 예상됩니다.

주요 정보

20.4%

수익 성장률

21.4%

EPS 성장률

Pharmaceuticals 수익 성장17.1%
매출 성장률11.5%
향후 자기자본 수익률28.4%
애널리스트 커버리지

Good

마지막 업데이트19 Jun 2024

최근 미래 성장 업데이트

Recent updates

Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark

Apr 16
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Mar 03
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00

Feb 05
Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00

Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Jan 07
Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly

Nov 14
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jun 01
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Mar 01
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jul 25
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture

Jun 02
Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture

Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

May 25
Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Feb 18
A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00

Jan 27
Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00

Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly

Jan 04
Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly

Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock

Dec 14
Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock

A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Nov 07
A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Sep 30
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?

Sep 01
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?

Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

Jul 02
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly

I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease

Jun 01
I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease

Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate

May 14
Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate

Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

Mar 23
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?

The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More

Mar 02
The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More

Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?

Feb 10
Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?

Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?

Jan 19
Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?

Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?

Dec 29
Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?

Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?

Dec 08
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?

Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%

Nov 16
Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%

수익 및 매출 성장 예측

NSEI:TORNTPHARM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
3/31/2027152,05530,58131,40036,38914
3/31/2026136,56526,11029,79333,09929
3/31/2025120,95620,42622,69326,33828
3/31/2024107,27816,56428,33332,661N/A
12/31/2023104,74214,942N/AN/AN/A
9/30/2023102,33213,43224,21228,691N/A
6/30/202398,64212,692N/AN/AN/A
3/31/202396,20212,45217,94223,681N/A
12/31/202292,5808,312N/AN/AN/A
9/30/202288,7507,97215,57419,380N/A
6/30/202287,2108,012N/AN/AN/A
3/31/202285,0807,77216,00418,030N/A
12/31/202183,15812,189N/AN/AN/A
9/30/202182,02812,66915,01517,827N/A
6/30/202180,82812,609N/AN/AN/A
3/31/202180,04612,51916,70220,054N/A
12/31/202080,14312,417N/AN/AN/A
9/30/202079,85311,95713,69018,078N/A
6/30/202079,73311,297N/AN/AN/A
3/31/202079,39310,2479,86113,929N/A
12/31/201978,4885,593N/AN/AN/A
9/30/201979,3385,54310,46316,981N/A
6/30/201978,2284,893N/AN/AN/A
3/31/201976,7284,36311,35317,981N/A
12/31/201875,1418,161N/AN/AN/A
9/30/201869,8916,281N/AN/AN/A
6/30/201865,1216,531N/AN/AN/A
3/31/201859,4986,7811,0298,942N/A
12/31/201756,7276,556N/AN/AN/A
9/30/201756,3878,266N/AN/AN/A
6/30/201756,3878,296N/AN/AN/A
3/31/201758,1579,336N/A10,088N/A
12/31/201659,15410,014N/AN/AN/A
9/30/201660,14410,624N/AN/AN/A
6/30/201662,74413,644N/AN/AN/A
3/31/201666,66917,332N/A27,421N/A
12/31/201563,31516,299N/AN/AN/A
9/30/201559,60513,139N/AN/AN/A
6/30/201554,8659,439N/AN/AN/A
3/31/201546,5357,509N/A8,102N/A
12/31/201447,2478,649N/AN/AN/A
9/30/201445,7178,559N/AN/AN/A
6/30/201443,2677,709N/AN/AN/A
3/31/201441,8476,639N/A5,994N/A
12/31/201338,2915,308N/AN/AN/A
9/30/201336,1114,858N/AN/AN/A

애널리스트 미래 성장 예측

수입 대 저축률: TORNTPHARM 의 연간 예상 수익 증가율( 20.4% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: TORNTPHARM 의 연간 수익( 20.4% ) Indian 시장( 15.9% 보다 빠르게 성장할 것으로 예상됩니다. 15.9% 연간).

고성장 수익: TORNTPHARM 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: TORNTPHARM 의 수익(연간 11.5% ) Indian 시장( 9.5% 보다 빠르게 성장할 것으로 예상됩니다. 9.5% 연간).

고성장 수익: TORNTPHARM 의 수익(연간 11.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: TORNTPHARM 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 28.4 %)


성장 기업 발견